KNOWLEDGE BANK

Interviews

Engineering the Future of Pneumococcal Conjugate Vaccines (PCV)

PhD, Chemical and Biotechnology, Savitribai Phule Pune University. Manager-Manufacturing, Inventprise Inc
Walmik Karbhari Gaikwad PhD is a seasoned biopharmaceutical expert with years in vaccine RD and manufacturing His PhD research pioneered costeffective processes for pneumococcal conjugate vaccines holds scholarly publications international patents and serves on editorial boards Based in Seattle currently works on cGMPcompliant process development and production at Inventprise Inc

Articles

Nano-Carrier based Smart Drug Delivery Systems

Cancer is one of the leading causes of death but is surpassed by cardiovascular diseases Chemotherapy plays a vital role in treating undetectable cancer microfocuses and free cancer cells Chemotherapy utilises chemical substances to kill or stop cancer cell development regarding that cancer cells are developed often much faster than those are healthy ones

Research Insights

Factors to consider in developing individual pharmaceutical product quality risk profiles useful to government procurement agencies

Abstract Governments that procure pharmaceutical products from an Essential Medicine List EML bear special responsibility for the quality of these products In this article we examine the possibility of developing a pharmaceutical product quality risk assessment scheme for use by government procurement officials We use the Chinese EML as a basis and US recal

Case Studies

Effects Of Particle Size On The Triboelectrification Phenomenon In Pharmaceutical Excipients: An Experimental Case Study

Abstract Particle sizes play a major role to mediate charge transfer both between identical and different material surfaces The study probes in to the probable mechanism that actuates opposite polarities between two different size fractions of the same material by analyzing the charge transfer patterns of two different sizes of MCC Quantum scale calculations

Techno Trends

UK Scientist Develops Simulated Human Heart to Test Drugs\' Effects before Clinical Trials

Aquavit Pharmaceuticals Inc has launched a cuttingedge technology the AQUAGOLD fine touch It is a firstofitskind direct dermal application technology Helen Maddock a scientist from the Centre for Applied Biological and Exercise Sciences at Coventry University UK has developed a new technique to safely test a drugs cardiovascu

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Harnessing Artificial Intelligence

Anita-Ioana Visan

Anita-Ioana Visan, a Scientific Researcher 2nd degree, at the Laser-Surface-Plasma Interactions (LSPI) Laboratory, Lasers Department, National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, is an expert in nanopowders synthesis and characterisation, as well as thin coatings of calcium phosphates, biopolymers, flavonoids, antibiotics, and antimicrobial peptides synthesized by Pulsed Laser Deposition, Matrix Assisted Pulsed Laser Evaporation, and Combinatorial-MAPLE. Moreover, she has a profound knowledge of thin films characterisation methods, including UV-Vis, FTIR, XRD, SEM, AFM, fluorescence microscopy, electrochemical, magnetic induction, biodegradation, and antimicrobial tests. With her current research focusing on the cutting-edge fields of artificial neural networks, drug repurposing, and pharmaceutical AI, she is paving the way for innovative solutions that have the potential to revolutionise the field of medicine. If you would like to contact her, please use the following email address: anita.visan@inflpr.ro. Furthermore, you can find her professional profile at https://orcid.org/0000-0003-0539-4160.

 

Irina Negut

Irina Negut is a Scientific Researcher 2nd degree, at the National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, Romania. She has important experience in fabricating and investigating the characteristics and (bio) functionality of nano-sized/-structured materials (including composite and hybrid particles, thin films and laser-processed coatings). Her research activity includes coating synthesis by laser-assisted techniques. She is also highly experienced in evaluating the compositional and microstructural aspects of nanomaterials and coatings, but also in assessing their optical, thermal, electrical, and electrochemical properties. If you would like to contact her, please use the following email address: negut.irina@inflpr.ro. Her professional profile can be found at https://orcid.org/0000-0003-4038-7548.

 

2

Application of Artificial Intelligence in Development Safety Update Report Preparation

Maria Carolina Braga

Maria Carolina Braga holds a degree in Pharmaceutical Sciences with a specialization in Clinical Pharmacy. She has over 10 years of experience in pharmacovigilance and recently completed a master’s degree in Pharmacovigilance and Pharmacoepidemiology, focusing her research on the use of artificial intelligence in aggregate safety report writing.

3

Effect of Size of Protein Therapeutics on Brain Pharmacokinetics following Systemic Administration

Hsueh-Yuan Chang

Chang supports the preclinical-to-clinical PKPD translation and human efficacious dose prediction of new biological entities at Boehringer Ingelheim. Dr. Chang obtained his MS and Ph.D. in Pharmaceutical Sciences at the University at Buffalo. Under Dr. Dhaval Shah’s mentorship, Dr. Chang investigated antibody and protein therapeutic disposition in the rat brain using large-poremicrodialysis and developed a translational brain PBPK model for monoclonal antibodies.

 

Dhaval K Shah

Dhaval K Shah is an Associate Professor of Pharmaceutical Sciences at the State University of New York at Buffalo. Prior to becoming the faculty Prof. Shah served as a Principle Scientist in the ‘Translational Research-Modeling & Simulation’ group at Pfizer Inc. His research focuses on understanding the determinants for the absorption, distribution, metabolism, and elimination (ADME) of protein therapeutics. His lab uses the principles of Pharmacokinetics-Pharmacodynamics (PK-PD) Modeling & Simulation to support the discovery, clinical translation, and late phase development of novel biologics like engineered antibodies, multi-specific proteins, immuno-oncology agents, engineered T cells, and antibody-drug conjugates.

 

Shengjia Wu

Shengjia Wu is a PhD student in the pharmaceutical sciences at the State University of New York at Buffalo. His research focuses on understanding and modeling the macromolecule distribution in the central nervous system.

 

Yingyi Li

Yingyi Li gained her master’s degree of pharmaceutical sciences in University at Buffalo. When Yingyi was a master student, she was working in Dr. Dhaval Shah’s lab and became more experienced in PBPK modeling. Yingyi is currently a scientist in the field of pharmacometrics and translational PK-PD in Enhanced Pharmacodynamics.

 

4

Transforming Customer Engagement in Life Sciences Adopting Hybrid Commercial Models (HCMs)

Rohit K

 

 is a Practice Director at the Life Sciences IT Services team, leading commercial technology research and client engagements. He has worked with business and IT leaders on strategy, M&A, and market intelligence. Previously a Consultant at EY, Rohit holds an MBA from FMS, Delhi University, and an engineering degree from NIT Jalandhar.

5

Commissioning the 505(b)(2) Pathways in Hastening the Clinical Translation of Various Drugs via Nanotechnological Approaches

Saurabh Srivastava

Saurabh Srivastava is Associate Professor in Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Wockhardt research centre and Dr. Reddy’s Laboratories for development and commercialisation of various NDA and ANDA based products for different regulated markets. He is actively involved in execution of several Industrial and Govt. aided research projects for establishment of novel differentiated (505 b 2) product development. He has 02 Commercial Products, 10 International and National Patents, 01 Edited book, 10 Book chapters along with 25 research publications in Journals of International repute to his credit.

 

Saurabh Shah

Saurabh Shah is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Hyderabad. He has published 2 research papers, 4 review articles and 2 book chapters in renowned journals. His research focus lies in hastening the clinical translation of nanomedicine-based products from bench to bedside. He has also been involved in numerous industry research and development projects from laboratory to pilot scale up.

 

press releasesRead more...

Asia–US Clinical Data Collaboration Built on IHH's Clinical Data

Mitsui Co Ltd Mitsui Head Office Tokyo President and CEO Kenichi Hori has entered a service agreement with Oncoshot Pte Ltd Oncoshot on the utilization of Oncoshots proprietary clinical

Teijin, Teijin Regenet and Shinshu University Hospital Launch Joint Research to Strengthen CAR-T Cell Therapy Manufacturing Capabilities in Japan

Teijin Limited Teijin Regenet Co Ltd and Shinshu University Hospital today announced that they have entered into a joint research agreement regarding manufacturing technologies for cell and gene

VVMF, Australia’s First Viral Vector CDMO Receives TGA Manufacturing Licence

Viral Vector Manufacturing Facility Pty Ltd VVMF Australias first viral vector Contract Development and Manufacturing Organisation CDMO advises that the Therapeutic Goods Administration TGA

Oral insulin drug achieves a critical milestone

University of Sydney biotechnology spinout Endo Axiom is conducting its first study in human subjects to assess the safety and tolerability of different doses of oral insulin in healthy volunteers

Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies

Transcenta Therapeutics HKEX a global clinicalstage biopharmaceutical company with fully integrated capabilities in discovery RD and process development of antibodybased therapeutics

1cBio and Lee's Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio's PARP1 Inhibitor OC-3 for Oncology in Greater China

cBio a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved conditions including oncology and metabolic diseases and Lees Pharmaceutical

EventsRead more...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

22 - 24

Sep 2026

28 - 01

Sep 2026

LATEST NEWSRead more...

CordenPharma Expands Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Annually

CordenPharma is expanding its sterile injectable manufacturing capacity at its Caponago site in Milan Italy through a multiyear investment programme

Exegenesis Bio Enters into Collaboration with Modalis to Advance MDL-201 for Duchenne Muscular Dystrophy

Exegenesis Bio and Modalis Therapeutics have entered into a research collaboration and licence agreement to advance MDL an investigational treatment for Duchenne muscular dystrophy DMD

Schrödinger Forms Tectora Therapeutics to Advance Immunology and Inflammation Programmes

Schrdinger has announced the formation of Tectora Therapeutics The company was cofounded by Schrdinger New Enterprise Associates NEA and RA Capital Management

MannKind and Rose Pharma Partner to Develop Inhaled GLP-1 for Weight Management

MannKind and Rose Pharma have entered into a worldwide licensing and collaboration agreement to develop ROSE Technosphere an investigational inhaled GLP therapy for weight management

Rezubio Advances RZ-520 into Phase 1 Clinical Trial Following FDA and NMPA Clearances

Rezubio has announced the first cohort dosing in its Phase clinical trial of RZ following Investigational New Drug IND clearances from the US Food and Drug Administration FDA and Chinas National Medical

ZANVASTRO approved by FDA as first disease-modifying treatment for Alexander disease

Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for ZANVASTRO zilganersen to treat Alexander disease AxD in paediatric and adult patients